Akoya Biosciences (AKYA) and SAMBAI announced that Akoya’s PhenoCycler-Fusion system will be the foundational spatial proteomics technology used to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research. “We are excited that the PhenoCycler-Fusion is the spatial proteomics technology of choice for analyzing thousands of patient samples as part of this important initiative,” said Brian McKelligon, CEO of Akoya Biosciences. “A study of this size demands the high plex and high throughput of our solutions to generate data at the scale needed. We are honored to play a role in defining the factors that influence disparate outcomes in underserved populations.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Tikvah intends to vote against Quanterix’s proposed merger with Akoya
- Akoya Biosciences downgraded to Equal Weight from Overweight at Stephens
- Cautious Outlook on Akoya Biosciences Amid Acquisition Uncertainties and Mixed Financial Performance
- Hold Rating on Akoya Biosciences Amid Acquisition Uncertainties and Financial Challenges
- Akoya Biosciences Reports 2024 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue